Dual CG family. We've both served 17 years. E6 & E7 6 children

Missed plenty of life's precious mo serve in this volunteer service

Sworn to defend 2

If we

Hold the Line Exposing Military Corruption during COVID-19


28

submit

can keep

111C

#HoldTheLine




n to S Korea

HOLDTHELME



#HoldtheLine

1. This presentation will show irrefutable evidence that the DoD, in concert with the FDA and CDC, sought to create the conditions to mandate a vaccination campaign for DoD that was neither necessary nor legal.



On August 24, 2021 Secretary of Defense Lloyd Austin signed a memo for the mandatory vaccination against Covid 19 for all Service Members

This memo explicitly states that the only vaccines for use will, *"Receive full licensure"* from the Food and Drug Administration (FDA), in accordance with FDA-approved labeling and guidance."



SECRETARY OF DEFENSE 1000 DEFENSE PENTAGON WASHINGTON, DC 20301-1000

MEMORANDUM FOR SENIOR PENTAGON LEADERSHIP COMMANDERS OF THE COMBATANT COMMANDS DEFENSE AGENCY AND DOD FIELD ACTIVITY DIRECTORS

SUBJECT: Mandatory Coronavirus Disease 2019 Vaccination of Department of Defense Service Members

To defend this Nation, we need a healthy and ready force. After careful consultation with medical experts and military leadership, and with the support of the President, I have determined that mandatory vaccination against coronavirus disease 2019 (COVID-19) is necessary to protect the Force and defend the American people.

Mandatory vaccinations are familiar to all of our Service members, and mission-critical inoculation is almost as old as the U.S. military itself. Our administration of safe, effective COVID-19 vaccines has produced admirable results to date, and I know the Department of Defense will come together to finish the job, with urgency, professionalism, and compassion

I therefore direct the Secretaries of the Military Departments to immediately begin full vaccination of all members of the Armed Forces under DoD authority on active duty or in the Ready Reserve, including the National Guard, who are not fully vaccinated against COVID-19.

Service members are considered fully vaccinated two weeks after completing the second dose of a two-dose COVID-19 vaccine or two weeks after receiving a single dose of a one-dose vaccine. Those with previous COVID-19 infection are not considered fully vaccinated.

Mandatory vaccination against COVID-19 will only use COVID-19 vaccines that receive full licensure from the Food and Drug Administration (FDA), in accordance with FDA-approved labeling and guidance. Service members voluntarily immunized with a COVID-19 vaccine under FDA Emergency Use Authorization or World Health Organization Emergency Use Listing in accordance with applicable dose requirements prior to, or after, the establishment of this policy are considered fully vaccinated. Service members who are actively participating in COVID-19 clinical trials are exempted from mandatory vaccination against COVID-19 until the trial is complete in order to avoid invalidating such clinical trial results.

Mandatory vaccination requirements will be implemented consistent with DoD Instruction 6205.02, "DoD Immunization Program," July 23, 2019. The Military Departments should use existing policies and procedures to manage mandatory vaccination of Service members to the extent practicable. Mandatory vaccination of Service members will be subject to any identified contraindications and any administrative or other exemptions established in Military Department policy. The Military Departments may promulgate appropriate guidance to carry out the requirements set out above. The Under Secretary of Defense for Personnel and

1. https://media.defense.gov/2021/Aug/25/2002838826/-1/-1/0/MEMORANDUM-FOR-MANDATORY-CORONAVIRUS-DISEASE-2019-VACCINATION-OF-DEPARTMENT-OF-DEFENSE-SERVICE-MEMBERS.PDF

THE

ORDER

Ask yourself:

> Do you know if the military is receiving fully approved product, or are other products being used as substitutes?

> Back to Timeline

WILLING TO RISK IT ALL AND STAND STRONG

#HOLDTHELINE

AUG 2 4 2021





+ 1 BABY

FULLY LICENSED

Per the Public Health Service Act, Licensure of a Biologic is a multifaceted process:

Approval of a Biologics Licensing Application 1.

are approved in the Application submitted to the FDA

Each Label **must** possess:

- The Proprietary Name of the Product
- The License Number 2.
- The Name and Address of the Manufacturer 3.
- The Expiration Date 4.

https://www.law.cornell.edu/uscode/text/42/262

TSGT. AIR 9 YRS IN **NEDI UANE** COUNTLESS SACRIFIN OSF MY OPPORTUNI RETIREMENT, MY HEALTH INSURAN SCHOOL BENEFIIS. I'VE HAD THE INFECTION AND RECOVER 赐 I HAVE IMMUNITY. 🐻 IF IMMUNITY IS THE GOAL WHY DOESN'T MY IMMUNITY COUNT?

What is required to be a "fully licensed" product ?

- 2. Limited to the manufacturing process and locations that
- 3. Labeling Requirements that are approved by the FDA

Ask yourself:

- > Do you know what it means if you have a BLA approval letter?
- \succ Is the manufacturer using the same facilities, and the same equipment, and the same process to create the drug as is specified in the BLA approval, or has it been changed since the letter was written?
- > Do you know the impact of label laws on this process?

- > Do you know that the vial you receive must say COMIRNATY to be a fully approved product?
- > Did you receive a vial that said "Pfizer-Biontech COVID-19 vaccine?"
- > Do you know what a "BLA approved" lot is?
- > Did you receive an approved lot?
- > Is/ Was the product you received within its expiration date?



THE PRODUCT IS NOT THERE

After 5 months of operating, they don't have any approved product at all yet?

Pfizer-BioNTech COVID-19 Vaccine Comparisons

	Purple Vial/Cap	Gray Vial/Cap	Orange Vial/Cap
Buffer	Phosphate Buffer Solution (PBS)	Tromethamine (Tris)	Tromethamine (Tris)
Age Group	12 years and older	12 years and older	5 – 11 years
FDA EUA or BLA Status*	BLA (approved 23 Aug 21) (EUA for ages 12 – 15)	BLA (approved 16 Dec 21) (EUA for ages 12 – 15)	EUA (authorized 29 Oct 21)
Part of DoD Mandate	Yes	Not yet** (per ASD(HA) & DHA)	N/A
DAF Inventory (cao 18 Jan 21) - % BLA lots - % EUA lots	89,604 doses - BLA: 13,266 (14.8%) - EUA: 76,388 (85.2%)	None	30,730 doses - BLA: N/A - EUA: 100%
Lots with COMIRNATY label	None	None	N/A

*FDA EUA (Emergency Use Authorization). BLA (Biologics License Application or "Full Approval") **Individuals who receive Pfizer-BioNTech gray vial/cap meet the FHP requirement and can be documented in ASIMS and EHR

ARMY RESERVE SGT 12 YEARS MARRIED + 4 KIDS APPLIED FOR RE, WILL GET OUT IF DENIER

#HOLDTHELINE

COVID-19 Vaccine Operations


cao 24 Jan 2022

Integrity - Service - Excellence

See date, this is 5 months post approval

Ask yourself: is operating without approved else is this situation happening? Who else is receiving substitutes?

18



NIH U.S. NATIONAL LIBRAI	ARY OF MEDICINE REPORT ADVERSE EVENTS RECALLS
	ALL DRUGS HUMAN DRUGS ANIMAL DRUGS MORE WAYS TO SEARCH V comirnaty
	HOME + NEWS FDA RESOURCES + NLM SPL RESOURCES + APPLICATION DEVELOPMENT SUPPORT HELP
SEARCH RESULTS	S FOR: comirnaty (0 results)
No Drug Package Lab	bels found. SHARE 🔤 🛨
	About DailyMed Customer Support Copyright Privacy Web Accessibility
	National Institutes of Health U.S. National Library of Medicine Health & Human Services

16 HOW SUPPLIED/STORAGE AND HANDLING

COMIRNATY Suspension for Intramuscular Injection, Multiple Dose Vials are supplied in a carton containing 25 multiple dose vials (NDC 0069-1000-03) or 195 multiple dose vials (NDC 0069-1000-02). A 0.9% Sodium Chloride Injection, USP diluent is provided but shipped separately, and should be stored at controlled room temperature 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. The provided 0.9% Sodium Chloride Injection, USP diluent will be supplied either as cartons of 10 mL single-use vials manufactured by

NIH) U.S. NATIONAL LIBRARY OF MEDICINE	REP	ORT ADVERSE EVENTS RECALLS		
DAILYMED	ALL DRUGS HUMAN DRUGS ANIMAL DRUGS Enter drug, NDC code, drug class, or Set ID	MORE WAYS TO SEARCH V	Г	
HOME	+ NEWS FDA RESOURCES + NLM SPL RESOURCES + APPLICATION DEVI	ELOPMENT SUPPORT HELP		BLA Approved
				(0069-100
NEWS: DailyMed Announcements				(0069-100
		PRINT 🖶 SHARE 🔤 🚹		
NEWS FROM THE YEAR 2021	for its COVID 10 version			
Pfizer received FDA BLA license on 8/23/2021 Posted: September 13, 2021				
	COVID-19 vaccine for use in individuals 16 and older (<u>COMIRNATY</u>). At proved new COVID-19 vaccine tradename COMIRNATY and listed 2 nev adename.			"Pfizer does r the new ND
	ict with these new NDCs and labels over the next few months while El ibution. As such, the CDC, AMA, and drug compendia may not publish th uced with the BLA labels.			

Ask yourself:

> If Pfizer hasn't produced any approved product yet, when did they plan on producing it, if ever? > Was the intent of saying it is "interchangeable" simply to give cover for Pfizer's potential losses from mass *manufacture of EUA product?*

AND WON'T

USPI_Comirnaty_COVID 19 Vaccine_mRNA_suspension for injection.PDF

NDC Codes:	EUA NDC Codes:
00-03)	(59267-1000-02)
00-02)	(59267-1000-03)

not plan to produce any new product with C codes, while EUA Authorized product is still available"

> Back to Timeline

rs of service le provider foi my wife and 4 children. I have a son who has to have healthcare to survive. It is a scary time. #holdtheline



USCG LTJG 2.5 YEARS OF SERVICE OWE 2.5 YEARS RISKING MONETARY PAYBACK, NJP/COURT MARTIAL, AND DISCHARGE. I WILL #HOLDTHELINE FOR THOSE WHO FEEL THEY CAN'T

WHAT

THIS?

IS

Codes ending in '2' and '3' Corresponding to BLA Approval

Inactive Ingredients

ALC-0159 (UNII: PJH39UMU6H) ALC-0315 (UNII: AVX8DX713V) POTASSIUM CHLORIDE (UNII: 660YQ98I10) MONOBASIC POTASSIUM PHOSPHATE (UNII: 4J9FJ0HL51) SODIUM CHLORIDE (UNII: 451W47IQ8X) SODIUM PHOSPHATE, DIBASIC, DIHYDRATE (UNII: 9425516E2T) SUCROSE (UNII: C151H8M554) 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOCHOLINE (UNII: 043IPI2M0K) CHOLESTEROL (UNII: 97C5T2UQ7J)

WATER (UNII: 059QF0KO0R)

Packaging

111	8 8			
	# Item Code	Package Description	Marketing Start Date	Marketing End Date
	1 NDC:0069-1000-02	195 in 1 CARTON		
	1 NDC:0069-1000-01	2.25 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product		
	2 NDC:0069-1000-03	25 in 1 CARTON		
	2 NDC:0069-1000-01	2.25 mL in 1 VIAL, GLASS; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Appli
BLA	BLA125742

Labeler - Pfizer Laboratories Div Pfizer Inc (134489525)

Registrant - Pfizer Inc (113480771)

Establishment

Name	Address	ID/FE
Pfizer Manufacturing Belgium NV		370156507

Ask yourself:

1. <u>https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=618348</u>

Ingredient Name	Strength
	0.4 mg in 2.25 mL
	3.23 mg in 2.25 mL
	0.07 mg in 2.25 mL
	0.07 mg in 2.25 mL
	2.7 mg in 2.25 mL
	0.49 mg in 2.25 mL
	46 mg in 2.25 mL
	0.7 mg in 2.25 mL
	1.4 mg in 2.25 mL

lication Nu	mber or Monograph Citation		Marketing Start Date		Marketing End Date
		08/2	3/2021	08/23/2021)
					_
		N	ote the Marketing	'Start'	•
			and 'End' dates	5	
				<i></i>	
FEI			Business Operations		
	ANALYSIS(0069-1000), MANUFACTURE(0069-1000), PACK(00	69-100	0), LABEL(0069-1000)		

> Why was the Marketing 'End' date made to be the same as the 'Start' date?

e	



TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER F - BIOLOGICS

PART 601 -- LICENSING

Subpart A - General Provisions

Sec. 601.5 Revocation of license.

(a) A biologics license shall be revoked upon application of the manufacturer giving notice of intention to discontinue the manufacture of all products manufactured under such license or to discontinue the manufacture of a particular product for which a license is held and waiving an opportunity for a hearing on the matter.

(b) (1) The Commissioner shall notify the licensed manufacturer of the intention to revoke the biologics license, setting forth the grounds for, and offering an opportunity for a hearing on the proposed revocation if the Commissioner finds any of the following:

(i) Authorized Food and Drug Administration employees after reasonable efforts have been unable to gain access to an establishment or a location for the purpose of carrying out the inspection required under § 600.21 of this chapter,

(ii) Manufacturing of products or of a product has been discontinued to an extent that a meaningful inspection or evaluation cannot be made,

(iii) The manufacturer has failed to report a change as required by § 601.12 of this chapter,

(iv) The establishment or any location thereof, or the product for which the license has been issued, fails to conform to the applicable standards established in the license and in this chapter designed to ensure the continued safety, purity, and potency of the manufactured product,

(v) The establishment or the manufacturing methods have been so changed as to require a new showing that the establishment or product meets the requirements established in this chapter in order to protect the public health, or

(vi) The licensed product is not safe and effective for all of its intended uses or is misbranded with respect to any such use.

(2) Except as provided in § 601.6 of this chapter, or in cases involving willfulness, the notification required in this paragraph shall provide a reasonable period for the licensed manufacturer to demonstrate or achieve compliance with the requirements of this chapter, before proceedings will be instituted for the revocation of the license. If compliance is not demonstrated or achieved and the licensed manufacturer does not waive the opportunity for a hearing, the Commissioner shall issue a notice of opportunity for hearing on the matter under § 12.21(b) of this chapter.

[64 FR 56451, Oct. 20, 1999]

TITLE

21

ents


AOLDTHELINE

Title 21, Ch. 1, Subchapter F, Part 601.5 goes into the revocation of a biologics license if the manufacturer states its intent to discontinue manufacture of the product they applied to have licensed

Ask yourself:

- > If Pfizer submitted an Expiration Date with their application, should FDA have revoked their Biologics License Application?
- \succ Is it legal to never intend to produce a drug with the FDA's knowledge of this intent?
- Pfizer has continued to manufacture EUA labeled lots after the approval of Comirnaty. Why?

Back to Timeline



HOW SUPPLIED/STORAGE AND HANDLING


The information in this section applies to the Pfizer-BioNTech COVID-19 Vaccine that is supplied in multiple dose vials with a purple cap. These multiple dose vials are supplied in a carton containing 25 multiple dose vials (NDC 59267-1000-3) or 195 multiple dose vials (NDC 59267-1000-2). After dilution, 1 vial contains 6 doses of 0.3 mL. Vial labels and cartons may state that after dilution, a vial contains 5 doses of 0.3 mL. The information in this Full EUA Prescribing Information regarding the number of doses per vial after dilution supersedes the number of doses stated on vial labels and cartons.

SEARCH RESULTS FOR:	Covid-19 vaccine (6 results)	STORAGE: Prior to dilution, store at -80°C to -60°C (-112°F to -76°F).
Sort By Relevance	SHARE I SHARE SHAR	Store in this carton to protect from light. DOSAGE AND ADMINISTRATION: After dilution, each vial contains 6 doses of 0.3 mL. See FDA-authorized Fact Sheet or scan
DRUG IMAGE NOT AVAILABLE	JANSSEN COVID-19 VACCINE (ad26.cov2.s) injection, suspension <u>NDC Code(s)</u> : 59676-580-05, 59676-580-15 Packager: Janssen Products, LP	QR code for information. MUST BE DILUTED BEFORE USE with sterile 0.9% Sodium Chloride Injection, USP (not supp After dilution, store the vaccine at 2°C to 25°C Discard after 6 hours. Contains no preservative. For use under Emergency Use Authorization.
UIEW MORE	MODERNA COVID-19 VACCINE (cx-024414) injection, suspension <u>NDC Code(s)</u> : 80777-273-10, 80777-273-15, 80777-273-98, 80777-273-99 Packager: Moderna US, Inc.	3 NO COPY NO COPY
DRUG IMAGE NOT AVAILABLE	PFIZER-BIONTECH COVID-19 VACCINE (bnt162b2) injection, suspension NDC Code(s): 59267-0078-1, 59267-0078-2, 59267-0078-4 Packager: Pfizer Manufacturing Belgium NV	Pfizer-BioNTech COVID-19 Vaccine Suspension for Intramuscular Injection 195 Multiple Dose Vials (after dilution each vial contains 6 doses of 0.3 mL) STORAGE: Prior to dilution, store at -80°C to -60°C (-112°F to -76°F). Store in this carton to protect from light. DOSAGE AND ADMINISTRATION: After dilution, each vial contains 6 doses of 0.3 mL.
DRUG IMAGE NOT AVAILABLE	PFIZER-BIONTECH COVID-19 VACCINE (bnt162b2) injection, suspension <u>NDC Code(s)</u> : 59267-1025-1, 59267-1025-3, 59267-1025-4 Packager: Pfizer Manufacturing Belgium NV	See FDA-authorized Fact Sheet or scan QR code for information. NO COPY
DRUG IMAGE NOT AVAILABLE	PFIZER-BIONTECH COVID-19 VACCINE (bnt162b2) injection, suspension NDC Code(s): 59267-1000-1, 59267-1000-2, 59267-1000-3 Packager: Prizer Manufacturing Belgium NV	P A A For i 3 For i
UNIT AVAILABLE	PFIZER-BIONTECH COVID-19 VACCINE (bnt162b2) injection, suspension NDC Code(s): 59267-1055-1, 59267-1055-4 Packager: Pfizer Manufacturing Belgium NV	DILU dilut Dilut

Ask yourself:

> Why would Pfizer move forward in labeling their product with compliant NDC codes, when: \geq 1. They had no intention of creating COMIRNATY or any other compliant lots until the EUA product was used up?

- \geq 2. It goes against label laws to misbrand product?
 - 1. https://labeling.pfizer.com/ShowLabeling.aspx?id=14471&format=pdf
 - 2. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=908ecbe7-2f1b-42dd-94bf-f917ec3c5af8



NO COPY

NDC 59267-1000-2

dosos of 0.2 ml

(after dilution each vial contains

UST BE DILUTED BEFORE USE ith sterile 0.9% Sodium iloride Injection,		PAA166261
SP (not supplied). ter dilution, store e vaccine at 2C to 25°C 5°F to 77°F). scard after 6 hours. ontains no eservative.	LOT: EXP:	IMPRINT AREA (reads this way) NO VARNISH NO COPY, NO INK,


THE LABELS

1. Pfizer's full **EUA** Prescribing Information provides compliant NDC label codes.

2. DailyMed search results for Comirnaty prior to 16 DEC 2021 showed NDC codes matching authorized product.

3. Pfizer's labels clearly indicate that it is for Emergency Use Authorization (EUA).

4. Emergency Use Authorization NDC code.



Back to Timeline

UNITED STATES NAVY DROPPED FROM SWEC PIPELINE BECAUSE OF THE SHOT IF I HAD MADE IT THROUGH THEY WOULD HAVE PULLED MY CONTRACT ANY WAY. DON'T HAVE AFAMILY OR CHILPREN BUT IT'S STILL

MEART BREAKING TO WATCH MY GOALS GO DOWN THE PRAIN BELAUSE OF A STUPID SHET.

NOW I'M JUST WAITING TO RE RATE OR GET SENT HOME.



HM3/E-4 I JOINED THE NAVY TO SERVE AN **HELP OTHERS IN THE MEDICAL** FIELD. NOW I FEEL BETRAYF NAVY MEDICINE.

#HOLDTHELINE

COVID-19 Vaccine, mRNA NDC 0069-1000-02 **COMIRNATY**[®] Suspension for Iniection, for Intramuscular Us **195 Multiple Dose Vials** after dilution each vial contains 6 doses of 0.3 mL TORAGE: Prior to dilution, store at -90°C to -60°C (-130°F to -76°F). Store in this carton to protect from light. DOSAGE AND ADMINISTRATION: Diluent (sterile 0.9% Sodium Chloride Injection, USP) supplied separately. se the provided diluent or an alternate brand of sterile 0.9% Sodium Chloride Injection, US After dilution, each vial contains 6 doses of 0.3 mL. lease see prescribing information for additional details including instructions for preparation, dosage and administration MUST BE DILUTED BEFORE USE with sterile 0.9% Sodium Chloride Injection, US After dilution, store the vaccine at 2°C to 25°C (35°F to 77°F). Discard after 6 hours. Contains no preservative PAA177818 See prescribing information or scan QR code. BIONTECH OPfizer Manufactured for BioNTech Manufacto IMPRINT AREA An der Goldgrube 12 55131 Mainz, Germany **NO VARNISH** Manufactured by NO COPY, NO INK US License No. 2229 COVID-19 Vaccine, mRNA PAA COMIRNATY for additional details including instructions for preparation, do r Intramuscular Use tion, MUS 195 Multiple Dose Vials BE DILUTED BEFORE USE with sterile 0.9% Sodium after dilution each vial contains 6 doses of 0.3 mL) TORAGE: Prior to dilution, store at -90°C to -60°C (-130°F to -76°F). Chloride Injection, USP. Store in this carton to protect from light. IOSAGE AND ADMINISTRATION: Diluent (sterile 0.9% Sodium After dilution, store the vaccine at 2°C to 25° (35°F to 77°F). oride Injection, USP) supplied separately. Use the provided diluer n alternate brand of sterile 0.9% Sodium Chloride Injection, USP. EXP NO CO Discard after 6 hours. dilution, each vial contains 6 doses of 0.3 mL. NO COP

COMIRNATY (FDA Approved)

COMIRNATY[®]

Dilution date and time:

US License No. 2229

XA


00

-

Ask yourself:

- > Why would Pfizer misbrand an EUA product?

EUA APPROVED PACKAGING




Pfizer-BioNTech COVID-19 Vaccine (EUA)

> Why can you not find any licensed product at pharmacies and bases in the United States? > Why haven't the EUA products been recalled/ destroyed by now if we have a licensed product?







- 1. The left image here shows that one vial of Pfizer-Biontech vaccine is 1.8 mL
- > What else was redacted, and what is the 2. The right image shows that COMIRNATY should be shipped as a 2 mL vial, with justification of allowing the redaction? a specific covering material. The rest of the description is classified (b) (4). This document, the November 8 Summary Basis for Regulatory Action – > Why would Pfizer NOT want to share how COMIRNATY, has numerous sections where this particular classification is cited it's made after a reasonable period of time for the redactions made. after they made their money back?
- 3. A (b) (4) classification is a Freedom of Information Act exemption code that "permits agencies, as a matter of discretion, to withhold trade secrets and commercial or financial information obtained from a person which is privileged or confidential."

FOIA

EXEMPTION

The COMIRNATY drug product is filled and stored at -90°C to -60°C in a 2 mL glass vial sealed with a bromobutyl rubber stopper and an aluminum seal with flip-off plastic cap.

> The stopper and caps are supplied by (b) (4)respectively.

Pfizer performed container closure integrity testing (CCIT) on the filled 2 mL glass vials test method. All acceptance criteria were met.

Ask yourself:

> Why would the cap need a FOIA exemption if anyone who handles the vials after approval can see them?

 \succ Why go to these lengths to conceal as much information as possible about their vaccine if it were such a miracle of science?

CW3 Active Army 18+ years of service **2 Iraq Deployments** 2 Afghan Deployments 5 kids

Single Income CVD recovered

...and it all means nothing to the Army if I don't get a shot.

Stay strong and be free. #HOLDTHELINE

Back to Timeline



https://www.fda.gov/media/151733/download

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=908ecbe7-2f1b-42dd-94bf-f917ec3c5af8 2.

https://www.acus.gov/recommendation/exemption-b4-freedom-information-3. act#:~:text=Exemption%20(b)(4)%20of%20FOIA%20permits%20agencies%2C%20as,which%20is%20privileged%20or%20confidential

Senior airman with

- almost 4 years in. Now facing a possible dishonorable discharge
- for refusing the shot

provide any updated information on a drug to healthcare professionals who administer the drug to patients.

2. The DHCP letter came with information on "BLA approved lot #'s" that were supposed to be compliant. The first seven lots in the "additional lot details" were manufactured prior to 23 AUG 2021, the last two were manufactured after the approval but retain EUA labels.

3. These lot #'s are all considered to be "BLA-compliant" minus the labeling. These cannot be deemed approved, or compliant, if they were manufactured before the approval date, and are marked with the EUA labels.

Ask yourself:

- > How many doses does this represent if lots have been arbitrarily given these lot #'s and passed off as BLA-compliant?
- > Is there no properly labeled "Comirnaty" vaccine in the United States?

					FIIO	020	
Back to							
Timeline		NDC11 Unit of Sale: This N	DC NDC11 Unit of Use:				
	Manufacturer	🗾 goes in NYSIIS Inventory	🔄 This NDC will be on the vi	🛛 Lot Number 🚽	Manufacture Date 🔽 I	Expiration Date	Date Last L
DHCP	Pfizer Inc.	59267-1000-02	59267-1000-01	FE3592	6/30/2021	2/28/2022	8
	Pfizer Inc.	59267-1000-03	59267-1000-01	FD7220	6/23/2021	11/30/2021	
	Pfizer Inc.	59267-1000-02	59267-1000-01	FF2588	7/4/2021	3/31/2022	8
	Pfizer Inc.	59267-1000-02	59267-1000-01	FD7220	6/23/2021	2/28/2022	8
LETTER & \\	Pfizer Inc.	59267-1000-02	59267-1000-01	FF2590	7/6/2021	3/31/2022	8
	Pfizer Inc.	59267-1000-02	59267-1000-01	FF8841	7/23/2021	3/31/2022	8
	Pfizer Inc.	59267-1000-02	59267-1000-01	FF2587	7/2/2021	3/31/2022	2
LOT $\#'S$	Pfizer Inc.	59267-1000-02	59267-1000-01	FF2593	7/6/2021	3/31/2022	5
$\square \frown \top \square \frown \blacksquare \square \frown \blacksquare \square \bigcirc \square \frown \blacksquare \square \bigcirc \square \frown \blacksquare \square \bigcirc \square$							

1. A Dear Health Care Professional (DHCP) letter is supposed to

August 23, 2021

RE: Pfizer-BioNTech COVID-19 Vaccine IMPORTANT PRODUCT INFORMATION Certain Pfizer-BioNTech COVID-19 Vaccine Lots authorized for Emergency Use comply with the Biologics License Application (BLA)


Dear Healthcare Professional

Pfizer, Inc. would like to provide you with updated and very important information related to the Pfizer-BioNTech COVID-19 Vaccine, authorized for emergency use by FDA under an Emergency Use Authorization (EUA). On August 23, 2021, FDA approved BioNTech's Biologics License Application (BLA) for COMIRNATY (COVID-19 Vaccine, mRNA), under U.S. License No. 2229. Many lots of Pfizer-BioNTech COVID-19 Vaccine are in circulation that were authorized for emergency use, and are labelled in accordance with the EUA. Some of these lots comply with the recently approved BLA for COMIRNATY and are therefore considered "BLA-approved" lots for administration to individuals 16 years of age and older. The lots that are BLA-approved for administration may be found at cvdvaccine-us.com/resources. For these lots, please see the COMIRNATY® full prescribing information for indication and usage, dosing and administration, and important safety information. This information can be found by scanning the QR code. Please note, it is imperative that you not discard any available EUA lots. These lots continue to be authorized for use under EUA in individuals 12 years of age and older, and for use as a third dose in certain mmunocompromised individuals. You can continue to use them up to the date of expiry.

Sincerel Donna Boyce

Senior Vice President, Global Regulatory Affairs

BIONTECH



Lot # NDC Codes: (59267 - 1000 - 02)(59267 - 1000 - 03)

FD7220		
FE3592		
FF2587		
FF2588	Mfd before	ap
FF2590		
FF2593		
FF8841		
FH8027	Mfd after a	ומס
FH8028		- - '
		•

Title 21, Chapter 1, Subchapter C, §207.37c - What restrictions pertain to the use of the NDC?

(a) A product may be deemed to be *misbranded* if an NDC is used:

(1) To represent a different drug than the drug for which the NDC has been assigned, as described in § 207.33;

(2) To denote or imply FDA approval of a drug; or

(3) On products that are not subject to parts 207, 607 of this chapter, or 1271 of this chapter, such as dietary supplements and medical devices.

(b) If marketing is resumed for a discontinued drug, and no changes have been made to the drug that would require a new NDC under § 207.35, the drug must have the same NDC that was assigned to it as described in § 207.33, before marketing was discontinued.

Ask yourself:

- > Are the FDA and DoD Perpetrating a fraud by implying that these EUA labeled vaccines are the licensed product?
- \succ Why would the DoD, an organization that needs to conduct its own Mission Analysis with its own personnel, simply take FDAs messaging at face value, along with all of the results of studies conducted by Pfizer, without demanding copies of the data to verify its own analysis and tailor the proliferation of the vaccine according to its own mission?





^{1. &}lt;u>https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-207/subpart-C/section-207.37</u>

How can the Department of Defense carry out a mandatory vaccination program that only has products marked for "Emergency Use"?

DoD is relying on 2 letters to carry out the mandate:

1. The "Dear Healthcare Professional" (DHCP) letter denoting "BLA Compliant" lots.

2. A memo from Terry Adirim, ASD(HA), directing DoD providers to use the EUA doses as if they were licensed product.

		HEALTH AFFAIRS
August 23, 2021 RE: Pfizer-BioNTech COVID-19 Vaccine IMPORTANT PRODUCT INFORMATION Certain Pfizer-BioNTech COVID-19 Vaccine Lots authorized for Emergency Use	COMIRNATY* (COVID-19 Vaccine, mRNA)	MEMORANDUM FOR ASSISTANT SEC RESERVE AI ASSISTANT SE RESERVE AI
comply with the Biologics License Application (BLA)	Manufactured for BioNTech Manufacturing GmbH An der Goldgrube 12 55131 Mainz, Germany Marketing Authorization Holder	ASSISTANT SE AND RESER DIRECTOR, DE
Dear Healthcare Professional, Pfizer, Inc. would like to provide you with updated and very important information related to the Pfizer-BioNTech COVID-19 Vaccine, authorized for emergency use by FDA under an Emergency Use	Manufactured by Pfizer Inc. New York, NY 11017 <u>US License No. 2229</u>	SUBJECT: Mandatory Vaccination of Ser and Comirnaty COVID-19 Vac
Authorization (EUA). On August 23, 2021, FDA approved BioNTech's Biologics License Application (BLA) for COMIRNATY (COVID-19 Vaccine, mRNA), under U.S. License No. 2229. Many lots of Pfizer-BioNTech COVID-19 Vaccine are in circulation that were authorized for emergency use, and are labelled in accordance with the EUA. Some of these lots comply with the recently approved		On August 23, 2021, the U.S. Food biologics license application for the Comin dose series for prevention of coronavirus di
BLA for COMIRNATY and are therefore considered "BLA-approved" lots for administration to individuals 16 years of age and older. The lots that are BLA-approved for administration may be found at cvdvaccine-us.com/resources. For these lots, please see the COMIRNATY®		older. Previously, on December 11, 2020, (EUA) for the Pfizer-BioNTech COVID-19 Comirnaty vaccine. Per FDA guidance, the health care providers should "use doses dis
full prescribing information for indication and usage, dosing and administration, and important safety information. This information can be found by scanning the QR code. Please note, it is imperative that you not discard any available EUA lots. These lots continue to be authorized		Consistent with FDA guidance, Do
for use under EUA in individuals 12 years of age and older, and for use as a third dose in certain immunocompromised individuals. You can continue to use them up to the date of expiry. Sincerely,		BioNTech COVID-19 vaccine and the Cor purpose of vaccinating Service members in "Mandatory Coronavirus Disease 2019 Va Members," August 24, 2021.
Donna Boyce		My point of contact for this guidant at (703) 681-8463 or michael.j.berecz.mil@
Senior Vice President, Global Regulatory Affairs	Phizer	
BIONTECH	2021TA035 v1.0	
		CC'

1 FDA, "Q&A for Comirnaty (COVID-19 Vaccine mRNA)," https://www.fda.gov/vaccines-blood-biologics/qacomimaty-covid-19-vaccine-mma, accessed September 10, 2021.

Surgeon General of the Army Surgeon General of the Navy Surgeon General of the Air Force

Joint Staff Surgeon

ASSISTANT SECRETARY OF DEFENSE 1200 DEFENSE PENTAGON TON, DC 20301-120

> RETARY OF THE ARMY (MANPOWER AND CRETARY OF THE NAVY (MANPOWER AND CRETARY OF THE AIR FORCE (MANPOWER **VE AFFAIRS** FENSE HEALTH AGENCY

vice Members using the Pfizer-BioNTech COVID-19 cines

and Drug Administration (FDA) approved the aty vaccine, made by Pfizer-BioNTech, as a twosease 2019 (COVID-19) in persons aged 16 years or the FDA issued an Emergency Use Authorization vaccine, which has the same formulation as the se two vaccines are "interchangeable" and DoD the EUA to administer the vaccinat

) health care providers will use both the Pfizerirnaty COVID-19 vaccine interchangeably for the accordance with Secretary of Defense Memorandum, cination of Department of Defense Service

ce is Colonel Michael J. Berecz, who may be reached mailmil

Back to

Timeline

ADIRIM.TERR Digitally signed by ADIRIM TERRY A. 152384 Y.A.152384712 7127 Date: 2021.09.14 11.02.05

Terry Adirim, M.D., M.P.H., M.B.A.

Ask yourself:

- > Why was Pfizer allowed to determine what lots are "BLA compliant?"
- > Where are the FDA inspectors who are supposed to ensure compliance with the BLA manufacturing process?
- > Why is DoD no longer enforcing the option to refuse when all product is EUA?

BASIS OF


MANDATES

USAF

SMSgt

yay of life !

theline



THE MEMO BY TERRY ADIRIM

In a guidance memo presented by Terry Adirim on September 14, 2021, there is a conflict with the guarantees presented within Secretary Austin's memo

2. Terry Adirim does *not* have the legal authority to advise any health administrator to present EUA labeled vials as licensed, or to create policy mandating EUA vaccines to service members. This authority is left solely to the discretion of the President.

3. As of JAN 2022, the President has not signed any waivers to informed consent.

4. There is a claim made in this memo that these products can be used "interchangeably." Interchangeable is defined by the FDA as:

"An interchangeable product is a biosimilar product that meets additional requirements outlined by the Biologics Price Competition and Innovation Act. As part of fulfilling these additional requirements, information is needed to show that an interchangeable product is expected to produce the same clinical result as the reference product in any given patient."

5. At present neither the Pfizer-Biontech vaccine nor Comirnaty are listed as biosimilar in the FDA's "Purple Book," a requirement to be considered "interchangeable."

United St Active Duty GE1/EE6 Honorably served 8. and would do it aga I love the Navy! #HOLDTHELINE

Ask yourself:

- > Who gave direction to Terry Adirim to put out a memo that directed usage of the Pfizer-Biontech COVID-19 vaccine as "interchangeable" with Comirnaty?
- > Why would the Assistant Secretary of Defense for Health Affairs presume to direct health care providers to administer certain products?



ASSISTANT SECRETARY OF DEFENSE

1200 DEFENSE PENTAGON WASHINGTON, DC 20301-1200

HEALTH AFFAIRS

MEMORANDUM FOR ASSISTANT SECRETARY OF THE ARMY (MANPOWER AND RESERVE AFFAIRS ASSISTANT SECRETARY OF THE NAVY (MANPOWER AND RESERVE AFFAIRS ASSISTANT SECRETARY OF THE AIR FORCE (MANPOWER AND RESERVE AFFAIRS DIRECTOR, DEFENSE HEALTH AGENCY

SUBJECT: Mandatory Vaccination of Service Members using the Pfizer-BioNTech COVID-19 and Comirnaty COVID-19 Vaccines

On August 23, 2021, the U.S. Food and Drug Administration (FDA) approved the biologics license application for the Comirnaty vaccine, made by Pfizer-BioNTech, as a twodose series for prevention of coronavirus disease 2019 (COVID-19) in persons aged 16 years or older. Previously, on December 11, 2020, the FDA issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine, which has the same formulation as the Comirnaty vaccine. Per FDA guidance, these two vaccines are "interchangeable" and DoD health care providers should "use doses distributed under the EUA to administer the vaccination series as if the doses were the licensed vaccine."

Consistent with FDA guidance, DoD health care providers will use both the Pfizer-BioNTech COVID-19 vaccine and the Comirnaty COVID-19 vaccine interchangeably for the purpose of vaccinating Service members in accordance with Secretary of Defense Memorandum, "Mandatory Coronavirus Disease 2019 Vaccination of Department of Defense Service Members," August 24, 2021.

My point of contact for this guidance is Colonel Michael J. Berecz, who may be reached at (703) 681-8463 or michael.j.berecz.mil@mail.mil.


> ADIRIM.TERR Digitally signed by ADIRIM.TERRY A. 152384 Y.A.152384712 7127 Date: 2021.09.14 11:02:05

Terry Adirim, M.D., M.P.H., M.B.A. Acting

cc:

Surgeon General of the Army Surgeon General of the Navy Surgeon General of the Air Force Joint Staff Surgeon

1 FDA, "Q&A for Comirnaty (COVID-19 Vaccine mRNA)," https://www.fda.gov/vaccines-blood-biologics/qacomimaty-covid-19-vaccine-mma, accessed September 10, 2021.





Back to

 22 YEARS OLD SERVED 3 OUT 6 YEARS BOUGHT A HOUSE AND READY TO RISK LOSING EVERYTHING

THIS ISN'T THE MILITARY I SIGNED UP TO BE APART OF

Terry Adirim has acted outside the scope of her authority

According to 10 USC, §1107a. Emergency use products

(a) Waiver by the President.-(1) In the case of the administration of a product authorized for emergency use under section 564 of the Federal Food, Drug, and Cosmetic Act to members of the armed forces, the condition described in section 564(e)(1)(A)(ii)(III) of such Act and required under paragraph (1)(A) or (2)(A) of such section 564(e), designed to ensure that individuals are informed of an option to accept or refuse administration of a product, may be waived only by the President only if the President determines, in writing, that complying with such requirement is not in the interests of national security.

By issuing a Directive that repeats claims made by FDA that the Pfizer product was "interchangeable," and directing military healthcare professionals to use EUA products as if they were approved, she has contributed to a violation of the tenets of 10 USC section 1107a by removing the option to accept or refuse the administration of a product that is under the provisions of an Emergency Use Authorization.

Judge Allen Winsor, in a denial for preliminary injunction order in Doe v Austin, stated: "Pfizer developed a COVID-19 vaccine, for which the FDA issued an Emergency Use Authorization ("EUA"). This allowed Pfizer to distribute the vaccine starting in December 2020. ECF No. 1-6 at 2-3. An EUA is not a full FDA license."

As the acting Assistant Secretary of Defense for Health Affairs, Terry Adirim has a wide range of personnel, from medical to legal, at her disposal to ascertain the legality of using the FDA's approval at face value. In fact, she has a duty to determine that an order is lawful or not, regardless if it came from the Secretary of Defense.

Ask yourself:


- the Office of the ASD(HA)?
- at any time in the near future?

SCOPE OF AUTHORITY

> Was Terry Adirim a witting accomplice in pursuing this mandate for all servicemembers? > Or, was Terry Adirim acting on her own to ensure that the orders of the SECDEF were reinforced by a memo from

> If the SECDEF and Terry Adirim were NOT aware that Comirnaty was not going to be made available, wouldn't the option to continue to refuse be made known to servicemembers after learning that it would not be made available







Reference Product

A reference product is the single biological product, already approved by FDA, against which a proposed biosimilar product is compared. A reference product is approved based on, among other things, a full complement of safety and effectiveness data. A proposed biosimilar product is compared to and evaluated against a *reference product* to ensure that the product is highly similar and has no clinically meaningful differences.

A product cannot be *legally* deemed interchangeable when there is no reference product.

Biologic Interchangeable Products are called "Biosimilars"

This means both products *must* be FDA approved. One cannot retain authorization while the other has approval.

Each biosimilar and each reference product are required to go through the entire approval process outlined in the Public Health Service Act Section 351(k) to be deemed interchangeable.

This is separate from Emergency Use Authorization, and they both have different statutory regulations.

REFERENCE PRODUCTS

#FEARTHELORD


#HOLDTHELIN



Ask yourself:

- > Is it intentionally fraudulent to make the claim that a product is interchangeable when it is not?
- > Were those responsible for the messaging that it is *"interchangeable" reasonably assumed to know this* definition when disseminating that messaging?

- Can Terry Adirim speak to this misrepresentation of the law?
- Is there any accountability for those denying service. members their right to informed consent?



US and Military Case Fatality Rates (CFR) Compared

MILITARY

CFR


- Sole

2. While the US CFR has dropped by 43% from it's average since the military vaccine mandate, the military CFR has increased by 54% from its average since the mandate. (fig 2)


3. Since the mandate, the military fully vaccinated rate rose 30% while the US rate only rose 10.6%. (fig 3)


Ask yourself:

> Why didn't the military CFR drop as low or lower than the US CFR since AUG 21? > Why did the military CFR increase 54% since the mandate while the US CFR decreased 43%?



1. The military's fully vaccinated rate rose 283% faster than the US rate since 24 AUG 21.







Military Medical and Religious Accommodations

Service members do not lose their Constitutional freedoms just because they signed on the dotted line to serve their country.

Medical waivers are granted based on:

- Contraindications
- Allergies or allergies to vaccine components
- Sensitivity
- "Undesirable reactions"
- Underlying health conditions (for example, based on immune competence, pharmacologic or radiation) therapy, pregnancy and/or previous adverse response to immunization).
- Evidence of immunity based on serologic tests, documented infection, or similar circumstances.

Medical doctors and PCMs used to have the freedom to grant medical waivers as they saw fit. However, these physicians are now afraid to write medical exemptions because they could have their medical license subjected to investigation or face disciplinary action for issuing exemptions, writing "too many" exemptions, or exemptions that are deemed "inappropriate."

<text><list-item><list-item><list-item><list-item><list-item>

TAGO 764A

Religious accommodations have been in place, specified in regulations, since 1971, and service members can request a religious accommodation for some or all vaccines based on their belief.

Ask yourself:

> Why are providers afraid to write medical exemptions since covid? > What kind of Command Climate fosters fear to do your duty as a medical provider, and do right by the Soldier, Sailor, or Airmen who needs a medical waiver to continue to serve honorably?

US Army s vears of service 8 deployments


am a true patriot and love my intry but will not comply to this unconstitutional order.

> last month and surviv till forced to take an al drug against my will

Back to

Timeline

oes what's rig



SSG 13 years active duty Iraq Afghanistan I've given everything to

my country, marriage, time, missed funerals, time away from my daughter

13 years, everything I've earned is at ris for an experiemental shot? 13 years to b discarded like a o piece of equipmen'

#HOLDTHE/

"Legitimate Religious Objection"

"First, a religion addresses fundamental and ultimate questions having to do with deep and imponderable matters. Second, a religion is comprehensive in nature; it consists of a belief system as opposed to an isolated teaching. Third, a religion often can be recognized by the presence of certain formal and external signs." (Africa v. Pennsylvania, 662 F.2d 1025, 1031 (3d Cir. 1981), the Third Circuit Court of Appeals)

A sincere religious believer doesn't forfeit his/her religious rights merely because s/he is not scrupulous in his/her observance or had never openly demonstrated those beliefs in the past. Furthermore, a person can become religious at any point in their life, even if they previously did not have religious objections.

Whether a belief is "sincerely held" is generally an issue of individual credibility. Evidence proving sincerely held religious beliefs is difficult to obtain in most cases, and often can be overcome, as sincerely held religious beliefs are not static and often change over time.

Religious Discrimination Based on Vaccination Refusal

Title VII makes it an unlawful employment practice for an employer to discharge or discriminate against an employee because of an individual's religion. The term religion "includes all aspects of religious observance and practice, as well as belief, unless an employer demonstrates that he is unable to reasonably accommodate an employee's or prospective employee's religious observance or practice without undue hardship on the conduct of the employer's business."


Back to Timeline

To establish a claim of religious discrimination under Title VII, the employee must show that (1) they held a sincere religious belief that conflicted with a job requirement; (2) they informed their employer of the conflict; and (3) they were disciplined for failing to comply with the conflicting requirement. Employers have a statutory obligation under Title VII to make reasonable <u>accommodations</u> for the religious observances of employees, but are not required to incur undue hardship.

DISCRIMINATION


RELIGIOUS


> Ask yourself: What is the percentage of service members who were judged to be "insincere" in their beliefs when they applied for their accommodation? Answer















"A way of life"

APPROVED

Amendment protection."

Some personnel who currently have approved RAs Service members who have approved (prior to COVID): RAs are able to:

- Conduct a move to both OCONUS and CONUS installations
- Deploy to combat theaters
- Rotate into non-combat theaters
- Attend training
- Attend schools
- Go on TDY

Many, if not all, of these personnel have not had their standing accommodations recognized. Guidance from the DoD has specifically stated that previously approved accommodations do not apply to covid, and have had their careers threatened just the same as those who do not have accommodations already in place. They face punishments and adverse actions that do not fall under the Uniform Code of Military Justice, and so go either unnoticed or the leadership turns their eyes to the grievous injustice happening to them.

Ask yourself:

20 LT, 0

ALMOST 2 UP IN A MONT

UPCOMING DEPLO

RA's

SUBMITTED RELIGIOU. REQUEST.

WILL HOLD FIRM TO MY FAIT THE VERY END.

LIKELY FACING LESS THAN HONORA **DISCHARGE IF MY REQUEST IS DENIE**

LIKELY HAVE TO PAY BACK ALL MY SCHOLARSHIP MONEY FROM COLLEGE.

NOT HOW I EXPECTED MY AF CAREER TO GO, BUT HERE WE ARE.

HOLD THE LINE. STAY STRONG. KEEP PRAYING.

Associate Justice Kathryn Mickle Werdegar, observed that a religious belief is something other than "a philosophy or a way of life." She further explained that "Religious beliefs need not be acceptable, logical, consistent, or comprehensible to others in order to merit First


- 11B Infantryman
- 68W Field Medic
- 11C Mortarman
- 19K M1 Armor crewman
- 13D Artilleryman
- 17E Electronic Warfare
- 153D UH-60 pilot

Back to Timeline


> If a Soldier can say they are an Atheist and still claim a religious belief, why are military leaders denying those who claim established religions their own beliefs?

> Why are senior military Chaplains fighting so hard to deny military service members their rights, with guidance that instructs them to rebut arguments about aborted fetal cells?

> Why is the institution of the DoD gathering and disseminating statements from religious leaders in support of vaccination to deny service members their right to request accommodation?











Defense Medical data

Raw data from the Defense Medical Epidemiology Database, accessible only by military medical providers.

Shows increases in all categories of acute and non-specific disease and injury.

HONOR L TOP OF CLA 3 MONTHS FRO. About to lose it all injection...

#HOLDTHELINE

6 YEARS

Back to Timeline

Date Obta	ined	2016	2017	2018	2019	2020	Avg Injuries Per Year 2016-2020	Jan to Oct 2021 Perce	ntage Change vs Avg in 2021
1/10/2022	O03 SPONTANEOUS Abortion	1,431	1,518	1,493	1,578	1,477	1499.4	4,182	278.91%
1/10/2022	Acute Pericarditis Hospitalized	49	54	58	48	54	52.6	41	77.95%
1/10/2022	I30 Acute Pericarditis Amb	535	538	522	531	499	525	850	1.619047619
1/19/2022	I30 Acute Pericarditis Amb	454	401	410	419	363		363	
1/10/2022	I40 Acute Myocarditis Hosp	17	17	18	33	14	19.8	15	75.76%
12/6/2021	I51.4 Myocarditis, Unspecified Amb	20	30	29	41	33		877	
1/10/2022	I40 Acute Myocarditis Amb	84	92	116	159	108	111.8	263	2.352415027
1/19/2022	I40 Acute Myocarditis Amb	59	62	62	93	67	68.6	118	172.01%
	140 141 I 51 ACUTE MYOCARDITIS MYOCARDITIS IN DISEASES CLASSIFIED ELSEWHERE						43.2		
8/29/2021	COMPLICATIONS AND ILL DEFINED DESCRIPTIONS OF HEART DISEASE		Total 21	.6 all five ye	ars			1239	2868.06%
1/10/2022	A00 to Z99 All disease and injuries Hosp	43,786	43,338	42,024	43,493	40,052	42538.6	54,776	128.77%
1/10/2022	AMS Hosp		43,338	42,024	36	27	40	25	62.50%
1/10/2022	AMS Amb	695	723	689	732	700	707.8	2,115	298.81%
1/10/2022			2,577	2,534	2,666	2,642	2579.4	6496	251.84%
	Anxiety Hosp	2,478					37091		
1/10/2022	Anxiety Amb	37,011	36,667	36,145	37,762	37,870		931,791	2512.18%
1/10/2022	appendicitis Hosp	648	654	690	795	717	700.8	1182	168.66%
1/10/2022	appendicitis Amb	1,977	1,930	2,298	2,633	2,593	2286.2	5,547	242.63%
1/10/2022	Bells Palsy Hosp	12	16	13	12	15	13.6	14	102.94%
1/10/2022	Bell's Palsy Amb	483	462 0	457 0	447 0	450 0	459.8	1338	291.00% 500.00%
1/10/2022	Brain dead Hosp	10	17		17	-	0.2 16.6		60.24%
1/10/2022 1/10/2022	Brain dead Amb	19 46	43	11 41	33	19 25	37.6	10 17	45.21%
	breast cancer Hosp	46 934	43 810	766		766	813.6	3963	45.21%
1/10/2022 1/10/2022	breast cancer Amb cerebral Infarction Hosp	934 107	108	124	792	107	108.2		79.48%
			848		95 888			86	
1/10/2022 8/29/2021	cerebral Infarction Amb	887 153	848 142	858 142	888 192	887	873.6 162.6	3136	358.97% 0.00%
	chest Pain Amb	6	5	142	192	184 3	4.6	1	21.74%
	cognitive Hosp	-	430	4	459			1772	
	cognitive Amb Cognitive malformations Hosp	484 270	236	403 211	236	421 197	439.4 230	1772 180	403.28% 78.26%
							10906.8		
	Congenital malformations amb	11,710	11,134	10,457	11,081	10,152		16,988	155.76%
	demylinating Hosp	41	74	59	45	40	51.8	34	65.64%
	demylinating Amb	785	737	690	677	648	707.4	3145	444.59%
	diseases of liver hosp	77	75	82	92	100	85.2	100	117.37%
	disease of liver Amb	1,994	2,053	2,063	2,234	2,322	2133.2	6187	290.03%
1/10/2022	-	63	57	70	53	67	62	60	96.77%
1/10/2022		1,319	1,167	1,072	1,036	960	1110.8	5269	474.34%
	dysmenohrea Hosp	29	35	32	30	22	29.6	12	40.54%
	dysmenohrea Amb	3,104	3,403	3,481	3,943	3,900	3566.2	12,539	351.61%
	dz of arteries Hosp	80	83	66	78	75	76.4	53	69.37%
1/10/2022	dz of arteries amb	3,164	2,965	2,938	3,096	2,860	3004.6	6069	201.99%
8/29/2021	E00 to E89 Endocrine nutritional and metabolic diseases	33,140	31,825	30,814	31,504	30,506	31557.8		0.00%
1/10/2022	esophageal cancer hosp	6	2	8	3	0	3.8	2	52.63%
1/10/2022	esophageal cancer amb	29	36	35	20	26	29.2	209	715.75%
1/10/2022	extra pyramidal hosp	12	24	23	11	14	16.8	5	29.76%
	extra pyramidal amb	1,509	1,474	1,339	1,371	1,338	1406.2	3669	260.92%
	eye disorder hosp	13	18	14	24	14	16.6	10	60.24%
	eye disorder Amb	6,044	6,013	5,647	6,312	5,623	5927.8	11,892	200.61%
	female infertility hosp	. 11	7	7	3	2	6	1	16.67%
	female infertility Amb	2,261	2,262	2,242	2,333	2,260	2271.6	10,713	471.61%
1/10/2022		25	29	30	30	21	27	18	66.67%
1/10/2022		66	79	71	85	65	73.2	403	550.55%
1/10/2022		599	455	412	415	392	454.6	2,460	541.14%
	HSV Hosp Hosp	4	روب ۸	412	ريب ۱	2	2.8	2,400	142.86%
	HSV Hosp Amb	4 1,734	4 1,779	1,724	4 1,786	2 1,678	1740.2	2350	135.04%
	·						1254.4		
	Neoplasm Hosp	1,452	1,341	1,174	1,211	1,094		922	73.50%
	Neoplasm Amb	41,557	39,139	37,751	38,887	36,044	38675.6	103,606	267.88%
1/10/2022	· ·	66	44	48	39	45	48.4	51	105.37%
1/10/2022		2,308	2,323	2,363	2,392	2,415	2360.2	53,846	2281.42%
	infertilty male	2,187	2,287	2,037	2,151	1,990	2130.4	7551	354.44%
	Inflammation NS Hosp	112	112	94	86	81	97	37	38.14%
1/10/2022	Inflammation NS Amb	664	669	560	555	457	581	998	171.77%
		34	36	32	25	28	31	31	100.00%
1/10/2022	Malasie & fatigue Hosp	7		01			3829		200.00/0

1. https://www.afhsc.mil/DMED

Defense Medical data

Raw data from the Defense Medical Epidemiology Database, accessible only by military medical providers.

Shows increases in all categories of acute and non-specific disease and injury.

TSCT. AIR 9 YRS IN 1 DEPLOYMEN COUNTLESS SACRIFIC I'LL LOSE MY OPPORTUNIT RETIREMENT, MY HEALTH INSURAL SCHOOL BENEFITS. I'VE HAD THE INFECTION AND RECOVED. I HAVE IMMUNITY. IF IMMUNITY IS THE COAL WHY DOESN'T MY IMMUNITY COUNT?

Service States

Back to Timeline

	2016	2017	2018	2019	2020	Avg Injuries Per Year 2016-2020	Jan to Oct 2021	Percentage Change vs Avg in 202
1/10/2022 Migraines Hosp	176	159	127	134	117	142.6	96	67.32%
1/10/2022 Migraines Amb	15,734	15,715	16,462	17,113	16,327	16270.2	66,640	409.58%
1/10/2022 Neoplasm Hosp	1,452	1,341	1,174	1,211	1,094	1254.4	922	73.50%
1/10/2022 Neoplasm Amb	41,557	39,139	37,751	38,887	36,044	38675.6	103, 606	#VALUE!
1/10/2022 Ovarian Cancer Hosp	11	5	11	3	6	7.2	2	27.78%
1/10/2022 Ovarian Cancer Amb	121	88	73	82	69	86.6	181	209.01%
1/10/2022 PE hosp	164	168	160	171	170		169	101.44%
1/10/2022 PE Amb	677	701	669	716	968	746.2	3,164	424.02%
1/10/2022 Pituitary Brain tumor hosp	0	0	0	1	0	0.2	0	0.00%
1/10/2022 Pituitary Brain tumor amb	8	8	7	7	7	7.4	14	189.19%
1/10/2022 Pregnancy Amb	64,198	65,751	66,026	70,590	71,111	67535.2	173,741	257.26%
1/10/2022 M62.82 Rhabdomyolysis Hosp	216	209	227	222	198	214.4	440	205.22%
1/10/2022 M62.82 Rhabdomyolysis Amb	706	696	740	755	669	713.2	5,162	723.78%
1/10/2022 SAH Hosp	27	13	16	19	19	18.8	17	90.43%
1/10/2022 SAH Amb	219	139	134	170	196	171.6	616	358.97%
1/10/2022 seizures hosp	27	20	21	32	20	24	21	87.50%
1/10/2022 seizures Amb	196	148	130	150	123	149.4	489	327.31%
1/10/2022 suicide	359	496	530	570	550	501	1798	358.88%
1/10/2022 tachycardia hosp	49	72	59	65	53	59.6	39	65.44%
1/10/2022 tachycardia amb	845	814	893	903	849		2,595	301.46%
1/10/2022 TB Hosp	5	11	כנט ר	905 15	049 F	8.6	2,595	34.88%
1/10/2022 TBAmb	1,115	694	488	449	238		3 467	78.25%
	-							
1/10/2022 testicular cancer hosp	49	37	39	43	19		27	72.19%
1/10/2022 testicular cancer Amb	1,156	1,008	866	880	889		3537	368.51%
1/10/2022 Thyroid dysfunction hosp	125	108	120	121	103	115.4	84	72.79%
1/10/2022 Thyroid dysfunction amb	8,074	7,696	7,357	7,289	6,891	7461.4	22,620	303.16%
1/10/2022 TIA Hosp	41	43	34	29	26	34.6	25	72.25%
1/10/2022 TIA Amb	509	453	491	485	467	481	795	165.28%
1/10/2022 Tinnitis Hosp								
1/10/2022 Tinnitis Amb	3,112	3,132	3,302	3,759	3,985	3458	21,771	629.58%
1/10/2022 vein dz hosp	186	179	145	176	126	162.4	113	69.58%
1/10/2022 vein dz amb	10,027	9,082	8,575	9,321	8,106	9022.2	16,286	180.51%
1/10/2022 G46 Vascular Syndromes of brain in cerebrovascular diseases Hosp	2	1	2	1	1	1.4	0	0.00%
1/10/2022 G46 Vascular Syndromes of brain in cerebrovascular diseases Amb	81	62	69	59	64	67	176	262.69%
1/19/2022 U07.1 COVID-19	0	0	0	0	1,911	382.2	116,037	30360.28%
T50.B95A Adverse effect of other viral vaccine, initial encounter		Total fo	r five years 9	914		182.8	1281	700.77%
Date Obtained	2016	2017	2018	2019	2020			
							Jan to Nov 2021	
1/19/2022 AUU to 299 All disease and injuries Hosp	43.786	43.338	42.024	43.493				
	43,786	43,338 2.058.379	42,024	43,493	40,052	2045555.8	54,776	1051.67%
1/19/2022 A00 to Z99 All disease and injuries Amb	2,059,630	2,058,379	<mark>2,022,663</mark> 2	2,110,383	40,052 1,976,724	2045555.8 31557.8	54,776 21,512,583	1051.67% 424 79%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB	2,059,630 2 33,140	2,058,379 31,825	2,022,663 2 30,814	2 <mark>,110,383</mark> 31,504	40,052 1,976,724 30,506	31557.8	54,776 21,512,583 134,053	424.79%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)	2,059,630	2,058,379	<mark>2,022,663</mark> 2	2,110,383	40,052 1,976,724	31557.8 38678.2	54,776 21,512,583	
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders	2,059,630 2 33,140 41,557	2,058,379 31,825 39,139	2,022,663 2 30,814 37,756	2,110,383 31,504 38,889	40,052 1,976,724 30,506 <u>36,050</u>	31557.8	54,776 21,512,583 134,053 114,645	424.79% 296.41%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism	2,059,630 2 33,140 41,557 11,533	2,058,379 31,825 39,139 11,122	2,022,663 2 30,814 37,756 10,851	2,110,383 31,504 38,889 11,773	40,052 1,976,724 30,506 36,050 11,429	31557.8 38678.2 11341.6	54,776 21,512,583 134,053 114,645 34,486	424.79% 296.41% 304.07%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs	2,059,630 33,140 41,557 11,533 660	2,058,379 31,825 39,139 11,122 654	2,022,663 2 30,814 37,756 10,851 633	2,110,383 31,504 38,889 11,773 602	40,052 1,976,724 30,506 36,050 11,429 704	31557.8 38678.2 11341.6 650.6	54,776 21,512,583 134,053 114,645 34,486 4,060	424.79% 296.41% 304.07% 624.04%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands	2,059,630 2 33,140 41,557 11,533 660 550	2,058,379 31,825 39,139 11,122 654 394	2,022,663 2 30,814 37,756 10,851 633 369	2,110,383 31,504 38,889 11,773 602 374	40,052 1,976,724 30,506 36,050 11,429 704 372	31557.8 38678.2 11341.6 650.6 411.8	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950	424.79% 296.41% 304.07% 624.04% 473.53%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases	2,059,630 2 33,140 41,557 11,533 660 550 117	2,058,379 31,825 39,139 11,122 654 394 96	2,022,663 2 30,814 37,756 10,851 633 369 104	2,110,383 31,504 38,889 11,773 602 374 90	40,052 1,976,724 30,506 36,050 11,429 704 372 110	31557.8 38678.2 11341.6 650.6 411.8 103.4	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238	424.79% 296.41% 304.07% 624.04% 473.53% 230.17%
1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System	2,059,630 2 33,140 41,557 11,533 660 550 117 82,435	2,058,379 31,825 39,139 11,122 654 394 96 81,998	2,022,663 2 30,814 37,756 10,851 633 633 369 104 81,382	2,110,383 31,504 38,889 11,773 602 374 90 85,012	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa	2,059,630 2 33,140 41,557 11,533 660 550 550 117 82,435 88,091	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712	2,022,663 2 30,814 37,756 10,851 633 633 369 104 81,382 86,417	2,110,383 31,504 38,889 11,773 602 374 90 85,012 91,503	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa1/19/2022C15 Malignant neoplasm of esophagus	2,059,630 2 33,140 41,557 11,533 660 660 550 117 82,435 88,091 29	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36	2,022,663 2 30,814 37,756 10,851 10,855 10,851 10,855 1000 100,855 1000 100,855 100000000000000000000000000000000000	2,110,383 31,504 38,889 11,773 602 374 90 85,012 91,503 20	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa1/19/2022C15 Malignant neoplasm of esophagus1/19/2022D69.3 immune thrombocytopenic purpura	2,059,630 2 33,140 41,557 11,533 660 550 550 117 82,435 88,091 29 189	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36 186	2,022,663 2 30,814 37,756 10,851 633 633 633 633 104 81,382 86,417 35 35	2,110,383 31,504 38,889 11,773 602 374 90 85,012 91,503 20 164	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 564	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa1/19/2022C15 Malignant neoplasm of esophagus1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022B50 Plasmodium Falciparum malaria (VALIDATION DATA)	2,059,630 2 33,140 41,557 11,533 660 660 550 117 82,435 88,091 29 189 36	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36 186 186 17	2,022,663 2 30,814 37,756 10,851 10,8	2,110,383 31,504 38,889 11,773 602 374 90 85,012 91,503 20 164 33	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 564 45	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS) D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa1/19/2022C15 Malignant neoplasm of esophagus1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022B50 Plasmodium Falciparum malaria (VALIDATION DATA)1/19/2022I21 Acute Myocardial Infarction	2,059,630 2 33,140 41,557 11,533 660 550 550 117 82,435 88,091 29 189	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36 87,712 36 186 17 615	2,022,663 2 30,814 37,756 10,851 633 633 369 104 81,382 86,417 35 86,417 35 39 39	2,110,383 31,504 38,889 111,773 602 374 90 85,012 91,503 20 164 33 608	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 261 564 45 1,650	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022B50 Plasmodium Falciparum malaria (VALIDATION DATA)1/19/2022G43 Migraine	2,059,630 2 33,140 41,557 11,533 660 660 550 117 82,435 88,091 29 189 36 579 15,734	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36 186 186 177 615	2,022,663 2 30,814 3 37,756 1 10,851 6 363 6 104 8 104 8 104 1 86,417 1 35 1 175 3 175 3 39 6 30 1 6,462 1	2,110,383 31,504 38,889 111,773 602 374 90 85,012 91,503 200 164 33 608 17,116	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11 629 16,331	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2 16271.4	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 564 564 45 1,650 73,490	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52% 451.65%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022B50 Plasmodium Falciparum malaria (VALIDATION DATA)1/19/2022G43 Migraine	2,059,630 2 33,140 41,557 11,533 660 550 117 82,435 88,091 29 29 189 36 36 579	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36 87,712 36 186 17 615	2,022,663 2 30,814 37,756 10,851 633 633 369 104 81,382 86,417 35 86,417 35 39 39	2,110,383 31,504 38,889 11,773 602 374 90 85,012 91,503 20 164 33 608 17,116 459	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11 629	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2 16271.4 439.4	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 261 564 45 1,650	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022L15 Malignant neoplasm of esophagus1/19/2022D59.3 immune thrombocytopenic purpura1/19/2022B50 Plasmodium Falciparum malaria (VALIDATION DATA)1/19/2022G43 Migraine1/19/2022Mild Cognitive	2,059,630 2 33,140 41,557 11,533 660 660 550 117 82,435 88,091 29 189 36 579 15,734	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36 186 186 177 615	2,022,663 2 30,814 3 37,756 1 10,851 6 363 6 104 8 104 8 104 1 86,417 1 35 1 175 3 175 3 39 6 30 1 6,462 1	2,110,383 31,504 38,889 111,773 602 374 90 85,012 91,503 200 164 33 608 17,116	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11 629 16,331	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2 16271.4 439.4 707.4	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 261 564 45 1,650 73,490 1,958	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52% 451.65%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa1/19/2022C15 Malignant neoplasm of esophagus1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022I21 Acute Myocardial Infarction1/19/2022G43 Migraine1/19/2022G43 Migraine1/19/2022Mild Cognitive1/19/2022G35 to G37 Demyelinating Diseases of the CNS	2,059,630 2 33,140 41,557 11,533 660 550 117 82,435 88,091 29 29 189 36 579 15,734 484	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36 87,712 36 186 17 615 15,714 430	2,022,663 2 30,814 37,756 10,851 633 369 104 81,382 86,417 35 86,417 35 175 39 630 16,462 403	2,110,383 31,504 38,889 11,773 602 374 90 85,012 91,503 20 164 33 608 17,116 459	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11 629 16,331 421	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2 16271.4 439.4	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 261 564 45 1,650 73,490 1,958	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52% 451.65% 445.61%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS) D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022D69.3 immune traction1/19/2022G43 Migraine1/19/2022G43 Migraine1/19/2022G43 Migraine1/19/2022G35 to G37 Demyelinating Diseases of the CNS1/19/2022G35 Multiple Sclerosis	2,059,630 2 33,140 41,557 11,533 660 550 117 82,435 88,091 29 189 36 579 15,734 484 785	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36 87,712 36 186 115,714 430 737	2,022,663 2 30,814 3 37,756 1 10,851 6 363 6 104 8 104 8 104 1 86,417 1 35 1 175 9 39 6 30 1 630 1 16,462 4 403 6 90 1	2,110,383 31,504 38,889 111,773 602 374 90 85,012 91,503 200 164 33 608 17,116 459 677	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11 629 16,331 421 648	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2 16271.4 439.4 707.4 404.4	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 261 564 45 1,650 73,490 1,958	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52% 451.65% 445.61% 486.85%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System	2,059,630 2 33,140 41,557 11,533 6600 550 1177 82,435 88,091 29 189 36 29 189 36 579 15,734 484 785 479	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36 87,712 36 15,714 430 737 391	2,022,663 2 30,814 37,756 10,851 10,851 10,851 10,851 104 104 104 104 104 104 104 104 104 10	2,110,383 31,504 38,889 11,773 602 374 90 85,012 91,503 20 164 33 608 17,116 459 677 400	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11 629 16,331 421 648 385	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2 16271.4 439.4 707.4 404.4 870.6	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 261 564 45 1,650 73,490 1,958 3,444 2,750	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52% 451.65% 445.61% 486.85% 680.02%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022E00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022B50 Plasmodium Falciparum malaria (VALIDATION DATA)1/19/2022G35 to G37 Demyelinating Diseases of the CNS1/19/2022G35 to G37 Demyelinating Diseases of the CNS1/19/2022G47.4 Narcolepsy and cataplexy1/19/2022G30 to G32 Other degenerative diseases of the nervous system	2,059,630 2 33,140 41,557 11,533 660 550 117 82,435 88,091 29 189 36 579 15,734 484 785 479 995	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 361 15,714 430 737 391 898	2,022,663 2 30,814 3 37,756 1 10,851 1 633 1 633 1 10,851 1 633 1 86,417 1 86,417 1 359 1 630 1 116,462 1 403 690 367 3 367 3	2,110,383 31,504 38,889 111,773 602 374 90 85,012 91,503 200 164 33 608 17,116 459 677 400 830	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11 629 16,331 421 648 385 766	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2 16271.4 439.4 707.4 404.4 870.6	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 564 564 45 1,650 73,490 1,958 3,444 2,750 2,097	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52% 451.65% 445.61% 445.61% 486.85% 680.02% 240.87%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022C15 Malignant neoplasm of esophagus1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022B50 Plasmodium Falciparum malaria (VALIDATION DATA)1/19/2022G35 to G37 Demyelinating Diseases of the CNS1/19/2022G35 to G32 Other degenerative diseases of the nervous system1/19/2022G30 to G32 Other degenerative diseases of the nervous system1/19/2022C7.4 Malignant Neuroendocrine tumors	2,059,630 2 33,140 41,557 11,533 660 550 117 82,435 88,091 29 189 36 579 15,734 484 785 479 995 560 167	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36 186 17 615 15,714 430 737 391 898 898	2,022,663 2 30,814 3 37,756 1 10,851 1 633 1 633 1 81,382 1 86,417 1 35 1 10,851 1 86,417 1 369 1 11,382 1 86,417 1 39 1 630 1 16,462 1 403 690 367 864 403 461	2,110,383 31,504 38,889 111,773 602 374 90 85,012 91,503 20 164 33 608 17,116 459 677 400 830 536 113	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11 629 16,331 421 648 385 766 489 117	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2 16271.4 439.4 707.4 439.4 707.4 404.4 870.6 509.2 126	54,776 21,512,583 134,053 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 261 261 564 45 1,650 1,650 1,650 1,958 3,444 2,750 2,097 2,054 440	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52% 451.65% 445.61% 445.61% 486.85% 680.02% 240.87% 403.38%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022E00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022G00 to t59 Diseases of the eye and adnexa1/19/2022L15 Malignant neoplasm of esophagus1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022G43 Migraine1/19/2022G35 to G37 Demyelinating Diseases of the CNS1/19/2022G30 to G32 Other degenerative diseases of the nervous system1/19/2022G30 to G32 Other degenerative diseases of the nervous system1/19/2022C74 Malignant Neuroendocrine tumors1/19/2022G30 to G32 Other degenerative diseases of the nervous system1/19/2022G30 to G32 Other degenerative diseases of the nervous system1/19/2022C74 Malignant Neuroendocrine tumors1/19/2022E28 Ovarian Dysfunction	2,059,630 2 33,140 41,557 11,533 660 550 117 82,435 88,091 29 189 36 36 579 15,734 484 785 479 995 560 167 862	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36 186 186 17 615 15,714 430 737 391 898 500 135	2,022,663 2 30,814 3 37,756 1 10,851 1 633 1 633 1 81,382 1 86,417 1 369 1 11,382 1 86,417 1 630 1 116,462 1 630 1 16,462 1 690 3 367 8 884 1 98 98 908 908	2,110,383 31,504 38,889 11,773 602 374 90 85,012 91,503 20 164 33 608 17,116 459 677 400 830 536 113 945	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11 629 16,331 421 648 385 766 489 117 1,022	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2 16271.4 439.4 707.4 439.4 707.4 404.4 870.6 509.2 126 934.6	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 261 261 564 45 1,650 73,490 1,958 3,444 2,750 2,097 2,054 440	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52% 451.65% 445.61% 445.61% 445.61% 445.61% 486.85% 680.02% 240.87% 403.38% 349.21%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa1/19/2022L15 Malignant neoplasm of esophagus1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022B50 Plasmodium Falciparum malaria (VALIDATION DATA)1/19/2022G43 Migraine1/19/2022G35 to G37 Demyelinating Diseases of the CNS1/19/2022G30 to G32 Other degenerative diseases of the nervous system1/19/2022G47.4 Narcolepsy and cataplexy1/19/2022C74 Malignant Neuroendocrine tumors1/19/2022C74 Malignant Neuroendocrine tumors1/19/2022C74 Pullionant Neuroendocrine tumors1/19/2022C74	2,059,630 2 33,140 41,557 41,557 11,533 11,533 660 550 117 82,435 88,091 29 189 36 579 15,734 484 785 479 995 560 167 862 660 678	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 361 15,714 430 737 430 737 391 391 391 393 393 393 393 393	2,022,663 2 30,814 3 37,756 3 10,851 3 633 3 10,851 3 10,851 3 403 3 86,417 3 86,417 3 10,851 3 10,851 3 104 3 86,417 3 175 3 630 3 16,462 3 403 3 690 3 367 3 403 3 900 3 908 3 908 3 908 6 6668 6	2,110,383 31,504 38,889 11,773 602 374 90 85,012 91,503 20 164 33 608 17,116 459 677 400 830 536 113 945 113	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11 629 16,331 421 648 385 766 489 117 1,022 968	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2 16271.4 439.4 707.4 439.4 707.4 404.4 870.6 509.2 126 934.6 746.2	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 261 261 564 45 1,650 1,650 1,650 1,650 1,958 3,444 2,750 2,097 2,054 440 4,086 3,489	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52% 451.65% 451.65% 445.61% 445.61% 486.85% 680.02% 240.87% 403.38% 349.21% 437.19%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS) D50 to D89 Diseases if the blood and blood forming organs and certain disorders involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G46 Vascular syndromes of brain in cerebrovascular diseases1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa1/19/2022C15 Malignant neoplasm of esophagus1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022G35 Negravitian Palciparum malaria (VALIDATION DATA)1/19/2022G35 to G37 Demyelinating Diseases of the CNS1/19/2022G30 to G32 Other degenerative diseases of the nervous system1/19/2022G30 to G32 Other degenerative diseases of the nervous system1/19/2022C74 Malignant Neuroendocrine tumors1/19/2022G30 to G32 Other degenerative diseases of the nervous system1/19/2022I26 Pulmonary Embolism1/19/2022I26 Pulmonary Embolism1/19/2022G37.7 Acute Transverse myelitis in demyelinating disease of CNS	2,059,630 2 33,140 41,557 41,557 1 11,533 660 6,600 550 11,533 1 6,600 1 11,533 1 6,600 1 11,533 1 82,435 1 88,091 1 189 36 190 36 579 1 15,734 484 785 479 995 560 167 862 678 678 678 46	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 36 186 186 186 17 615 15,714 430 737 391 898 500 135 936 701 936 701	2,022,663 2 30,814 3 37,756 1 10,851 1 633 1 633 1 10,851 1 633 1 86,417 1 86,417 1 369 1 110,851 1 86,417 1 367 3 116,462 1 403 690 367 3 864 1 98 908 908 668 668 48	2,110,383 31,504 38,889 111,773 602 374 900 85,012 91,503 200 164 33 608 17,116 459 677 400 830 536 113 945 113 945 716 35	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11 629 16,331 421 648 385 766 489 117 1,022 968 34	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2 16271.4 439.4 707.4 439.4 707.4 404.4 870.6 509.2 126 934.6 746.2 44	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 261 564 45 1,650 73,490 1,958 3,444 2,750 2,097 2,054 440 4,086 3,489 202	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52% 451.65% 445.61% 445.61% 486.85% 680.02% 240.87% 403.38% 349.21% 437.19%
1/19/2022A00 to Z99 All disease and injuries Amb1/19/2022E00 to E89 Endocrine nutritional and metabolic diseases AMB1/19/2022C00 to D49 Neoplasms (ALL CANCERS)D50 to D89 Diseases if the blood and blood forming organs and certain disorders1/19/2022involving the immune mechanism1/19/2022C15 to C26 Malignant neoplasms of digestive organs1/19/2022C73 to C75 Malignant neoplasms of thyroid and other endocrine glands1/19/2022G40 to G99 Diseases of the Nervous System1/19/2022G00 to G99 Diseases of the Nervous System1/19/2022H00 to H59 Diseases of the eye and adnexa1/19/2022C15 Malignant neoplasm of esophagus1/19/2022D69.3 immune thrombocytopenic purpura1/19/2022B50 Plasmodium Falciparum malaria (VALIDATION DATA)1/19/2022G35 to G37 Demyelinating Diseases of the CNS1/19/2022G30 to G32 Other degenerative diseases of the nervous system1/19/2022G30 to G32 Other degenerative diseases of the nervous system1/19/2022G30 to G32 Other degenerative diseases of the nervous system1/19/2022I26 Pulmonary Embolism	2,059,630 2 33,140 41,557 41,557 11,533 11,533 660 550 117 82,435 88,091 29 189 36 579 15,734 484 785 479 995 560 167 862 660 678	2,058,379 31,825 39,139 11,122 654 394 96 81,998 87,712 361 15,714 430 737 430 737 391 391 391 393 393 393 393 393	2,022,663 2 30,814 3 37,756 3 10,851 3 633 3 10,851 3 10,851 3 403 3 86,417 3 86,417 3 10,851 3 10,851 3 104 3 86,417 3 175 3 630 3 16,462 3 403 3 690 3 367 3 403 3 900 3 908 3 908 3 908 6 6668 6	2,110,383 31,504 38,889 11,773 602 374 90 85,012 91,503 20 164 33 608 17,116 459 677 400 830 536 113 945 113	40,052 1,976,724 30,506 36,050 11,429 704 372 110 80,786 79,529 26 161 11 629 16,331 421 648 385 766 489 117 1,022 968	31557.8 38678.2 11341.6 650.6 411.8 103.4 82322.6 86650.4 29.2 175 27.2 612.2 16271.4 439.4 707.4 439.4 707.4 404.4 870.6 509.2 126 934.6 746.2 44	54,776 21,512,583 134,053 114,645 34,486 4,060 1,950 238 863,013 280,206 261 261 261 564 45 1,650 1,650 1,650 1,650 1,958 3,444 2,750 2,097 2,054 440 4,086 3,489	424.79% 296.41% 304.07% 624.04% 473.53% 230.17% 10.48330592 323.38% 893.84% 322.29% 165.44% 269.52% 451.65% 451.65% 445.61% 445.61% 445.61% 486.85% 680.02% 240.87% 403.38% 349.21% 437.19%

1. https://www.afhsc.mil/DMED

Coercion

Coercion

- The Old Guard
- SM Accounts A-D


Vaccine Injury

- SM A
- SM B
- SM C
- SM D

E5/STAFF SERGEANT U.S. AIRFORCE 7.5 YEARS OF SERVICE ALL BENEFITS GONE YEARS OF SACRIFICE MISSEDBIRTHS. HOLIDAYS, DEATHS, FUNERALS. BIRTHDAYS. YEARS OF SELFLESS SERVICE. PROTECTINGRIGHTS **ANDFREEDOMS THAT AREN'T GRANTEDIN RETURN TO US SERVICE** MEMBERS. **WE CAN BOUNCE BACK** STRONGER, WE WILL BOUNCEBACK STRONGER, WEMUST **BOUNCE BACK** STRONGER

Infantry Officer Basic Course – 9SEP21 Publicly calling out peoples vaccine status.

Coercion & Vaccination Injuries



UNCLASSIFIED

Headquarters FS/HAAF Fort Stewart, GA 31314 02 September 2021

CHANGE 1 TO FRAGORD 112 (MANDATORY VACCINATION SUPPORT) TO 3RD INFANTRY DIVISION OPORD 20-34 (OPERATION MARNE HAMMER)

THIS SENIOR MISSION COMMANDER FSGA/HAAF DIRECTED FRAGORD HAS BEEN APPROVED FOR RELEASE BY LTC PEREZ-CRUZ, G3

during Coordination Back Brief (see Appendix 5: BDE Coordination Back Brief) 24 hrs. prior to arrival to enable efficient flow of personnel. See Appendix 10: Newman Gym By-Unit Timeline (TBP) & Appendix 11: Sabre Hall By-Unit Timeline (TBP). Add.

(i) (U) Upon Receipt of Order: DELETE ALL EXEMPTIONS for COVID-19 Immunizations in MEDPROS. No PERMANENT exemptions will be entered, pending further guidance from Corps. MT (Medical Temporary) Exemptions may be entered by BDE medical providers (PA, SURG) as clinically indicated IAW manufacturer's contraindications "Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine" (hyperlink: Comirnaty (COVID-19 Vaccine, mRNA) Adverse Reactions (Pfizer-BioNTech COVID-19 Vaccine) | Pfizer Medical Information - US). Add.

(j) (U) Provide one leader per BDE with CMD Authority to counsel declinations as per Appendix 7:

Back to Timeline 3rd Infantry Division Order Specifying deletion of Soldier medical records

Ask yourself:

- What underlying policies have been disseminated that gave Commanders the idea that calling out personal health information (PHI) was acceptable?
- What could lead to personnel being force vaccinated when legitimate medical records are being deleted?




Lloyd Austin has violated multiple federal laws by not divesting his stock interests in multiple companies and breaking his ethics agreement.

The penalties for these crimes can include up to <u>5 years in prison</u> as well as <u>\$50,000 fine for each incident</u> or forfeiture of compensation which he received or offered for the prohibited conduct, whichever amount is greater.

Lloyd Austin's significant financial interests in Tenet Healthcare Corporation are a direct conflict of interest with his order for the total force to be vaccinated as Tenet Healthcare facilities service areas where SMs would get vaccinations on the civilian market as many have been ordered to do.

Violation includes 18 U.S. Code § 208 - Acts affecting a personal financial interest

Lloyd Austin has no Form 4s showing promised divestment, which is a public announcement of insider stock transactions in a company. This is verified by link (4).




Conflict of

interest

Adobe Acrobat Document

Ethics agreement, signed by Lloyd Austin on 8 JAN 2021





- Ivermectin.



From the information provided, we can determine that these facts exist:

- There is no FDA-approved Comirnaty in stock
- There is no Comirnaty being produced
- \bullet
- The mandate for DoD as presented is unlawful

Therefore, we must come to these conclusions:

- must be immediately rescinded
- receiving the vaccine based on religious grounds
- as well as ethics commitments

On behalf of the American people, and military service members, we demand immediate investigations into the lack of transparency, and the flagrant disregard for the rule of law, by this Congressional body. Anything less further erodes and degrades the foundation of sacred trust that the American people place upon those who serve in the military.

16yrs of Sevi volunteered to Freedom" not for PENSION. The m can keep it. I will not submit

#HoldTheLine

Conclusions

DoD has knowingly violated the rights of servicemembers across ALL of the Services

The mandate for servicemembers to receive a "fully approved" vaccine is flawed at best and

Servicemembers must be allowed to exercise their Constitutional rights to be exempt from

• Terry Adirim has gone outside of the scope of her authority in issuing the memo directing healthcare professionals to treat EUA product as if it were fully authorized

Lloyd Austin has violated the trust of the US military, while being guilty of breaking Federal law,

